Jeffrey P. Libson is a Corporate and Securities partner in the Berwyn office of Pepper Hamilton LLP. He is the head of the firm’s life sciences practice. Mr. Libson’s practice is devoted primarily to the areas of securities law, venture financing, mergers and acquisitions, corporate governance and the commercialization, licensing and acquisition of intellectual property.
He represents a number of publicly traded and closely held life science companies in ongoing representations as outside general counsel. He also represents a number of nonprofit entities that support the life sciences industry.
Within the securities and venture financing practice areas, Mr. Libson has represented investment banks and issuers in public offerings (including initial public offerings) and private placements of equity and debt securities, and has represented both funding sources and companies in venture financing transactions.
Within the mergers and acquisitions practice area, Mr. Libson has represented buyers, sellers and investors in numerous acquisition, disposition and combination transactions, affecting both public and private companies. Company industries include biotech, diagnostics, pharmaceutical, health care and e-health, and communications, among others.
Within the intellectual property practice area, Mr. Libson has represented numerous companies, including pharmaceutical companies, biotechnology companies, consumer products companies, computer software developers and R&D contractors, in corporate partnering transactions, the acquisition and licensing of patents, trademarks, copyrights and trade secrets, and in the development of new products and technologies.
Mr. Libson is listed in The Best Lawyers in America in the specialties of biotechnology law and venture capital law and in Chambers USA: America’s Leading Lawyers for Business for his experience in mergers and acquisitions and private equity. He was selected as a Life Sciences Star in LMG Life Sciences in 2012 and 2013. He also was selected for inclusion on the 2014 Pennsylvania Super Lawyers list and was named to the 2011 Legal Elite list by Philadelphia SmartCEO magazine. Mr. Libson is a recipient of the Entrepreneurial Advocate Award given in connection with the Northeastern Pennsylvania Ben Franklin Innovation Awards. In 2011, he was recognized as Best Consultant to the life sciences industry in connection with the Philadelphia Business Journal Life Sciences Awards program.
Representative transactions in which Mr. Libson has participated include the following. He has represented:
Mr. Libson is the secretary and a member of the board of directors of the Pennsylvania Biotechnology Association. He also is a board member of BioStrategy Partners, a nonprofit organization that provides technology development and business guidance to early-stage life sciences ventures, and is a board member of the Pennsylvania Life Sciences Institute, a nonprofit organization that provides education and work force development for the life sciences industry.
- a venture capital backed biotechnology company, as lead counsel, in the company’s successful 2013 initial public offering
- a venture capital backed diagnostics company in its $850 million sale, following a strategic process whereby, with our assistance, it was positioned to execute an initial public offering or a private equity transaction, in addition to the sale
- a publicly traded biotechnology company, as regulatory counsel, in an underwritten public offering
- a publicly traded biotechnology company in the establishment of a “universal shelf” registration statement and an $80 million underwritten “take down” public offering
- a publicly traded biotechnology company in a $150 million private placement of convertible debt under Rule 144A
- one of the largest U.S. biotechnology venture capital fund and other venture capital funds (including global pharma corporate venture funds) in more than 300 financing and related transactions
- a biotechnology company in a coordinated international licensing and development program, including the licensing of patents and trade secrets from multiple U.S. and foreign patent holders, the negotiation and documentation of research and development agreements with multiple U.S. and foreign research institutions, and the negotiation and documentation of debt and equity financing to fund the research and development program
- a biotechnology company in a “corporate partnering” transaction with a multinational corporation, which included elements of research and development, intellectual property licensing, product manufacture and supply, along with a significant equity investment by the multinational corporation in the biotechnology company
- a venture capital-backed biotechnology company (vaccine development) in connection with its merger into a publicly traded biotechnology company
- a biotechnology company in connection with a multi million dollar private placement of its common stock
- a biotechnology venture capital fund in several public offerings of “portfolio company” securities
- several biotechnology companies in initial, follow on and mezzanine venture capital and institutional equity financing transactions.
Mr. Libson is an adjunct professor at The Wharton School of the University of Pennsylvania, where he teaches a graduate-level business course on life sciences entrepreneurship. He also is an adjunct professor at the Lehigh University School of Business and Economics where he teaches a graduate-level business course on venture capital financing.